Current Hepatitis Reports

, Volume 11, Issue 4, pp 250–255

Treatment of Chronic HCV Genotype 4 Infection

  • G. Esmat
  • M. El Raziky
  • M. El-Kassas
  • M. Hassany
  • M. E. Gamil
Global Perspectives: Middle East (SM Alavian and AI Sharara, Section Editors)

DOI: 10.1007/s11901-012-0146-2

Cite this article as:
Esmat, G., El Raziky, M., El-Kassas, M. et al. Curr Hepatitis Rep (2012) 11: 250. doi:10.1007/s11901-012-0146-2

Abstract

Hepatitis C virus genotype 4 (HCV4) is the most common type of hepatitis C virus (HCV) in the Middle East and Africa, in particular Egypt. Treatment with pegylated interferon and Ribavirin is still the standard regimen of care with overall response ranging between 50 and 60 %. New types of interferon (Y-shaped, Reiferon Retard,…), new DAAD (protease inhibitors, polymerase inhibitors, NS5A inhibitors….), and many off label drugs (Nitazoxanide, Vit.D…) may improve the treatment outcome of patients with HCV-4.

Keywords

HCV4-Pegylated interferon-new interferon molecules –DAATMiddle East

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • G. Esmat
    • 1
  • M. El Raziky
    • 1
  • M. El-Kassas
    • 2
  • M. Hassany
    • 2
  • M. E. Gamil
    • 2
  1. 1.Endemic Medicine DepartmentCairo UniversityCairoEgypt
  2. 2.Tropical Medicine DepartmentNational Hepatology and Tropical Medicine Research Institute (NHTMRI)CairoEgypt